<DOC>
	<DOCNO>NCT03054194</DOCNO>
	<brief_summary>Study E2730-A001-001 first-in-human , sequential ascend single dose , placebo-controlled study evaluate safety , tolerability , pharmacokinetics ( PK ) single oral dose E2730 healthy participant .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics E2730</brief_title>
	<detailed_description />
	<criteria>Nonsmoking , male female , age ≥18 year ≤55 year old time inform consent ( note : consider nonsmoker , participant must discontinue smoke least 4 week dose ) Body mass index ( BMI ) ≥18 &lt; 32 kilogram per meter square ( kg/m^2 ) Screening Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week dose Females breastfeed pregnant Screening Baseline ( document negative beta human chorionic gonadotropin [ βhCG ] ( human chorionic gonadotropin [ hCG ] ) test minimum sensitivity 25 International Units per Liter [ IU/L ] equivalent unit βhCG [ hCG ] ) . A negative urine pregnancy test require administration first dose per cohort . Females childbearing potential : Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( eg , total abstinence , intrauterine device , double barrier method [ condom plus diaphragm spermicide ] vasectomize partner confirm azoospermia hormonal contraceptive permit ) throughout entire study period 28 day study drug discontinuation Are currently abstinent , agree use double barrier method ( describe ) refrain sexual activity study period 28 day study drug discontinuation NOTE : All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . Males successful vasectomy ( confirm azoospermia ) female partner meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 28 day study drug discontinuation ) . No sperm donation allow study period 3 month study drug discontinuation . Evidence disease may influence outcome study within 4 week dose ( eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , participant congenital abnormality metabolism ) Any history seizure , include experienced childhood Any history gastrointestinal surgery may affect pharmacokinetic profile E2730 ( eg , hepatectomy , nephrectomy , digestive organ resection ) Screening Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment Screening Baseline A prolong QT/QT correct ( QTc ) interval ( QC interval correct use Fridericia 's formula [ QTcF ] &gt; 450 millisecond ) demonstrate ECG Screening Baseline ( base average triplicate ECGs ) . A history risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT Syndrome ) use concomitant medication prolong QT/QTc interval Left bundle branch block Screening Baseline Persistent systolic blood pressure ( BP ) &gt; 130 &lt; 100 millimeter mercury ( mmHg ) diastolic BP &gt; 85 &lt; 50 mmHg Screening Baseline Persistent heart rate le 50 beats/min 100 beats/min Screening Baseline History myocardial infarction , ischemic heart disease , cardiac failure Screening History clinically significant arrhythmia uncontrolled arrhythmia Known history clinically significant drug allergy Screening Baseline Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline Known human immunodeficiency virus positive Screening Active viral hepatitis ( A , B , C ) demonstrate positive serology Screening History drug alcohol dependency abuse within 2 year Screening , positive drug test ( include cannabinoids ) alcohol test Screening Baseline Intake caffeinated beverage food within 72 hour dose Intake nutritional supplement , juice , herbal preparation food beverage may affect various drugmetabolizing enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , Brussel 's sprout , mustard ] , charbroiled meat ) within 1 week dose Intake herbal preparation contain St. John 's Wort within 4 week dose Use prescription drug within 4 week dose Intake overthecounter ( OTC ) medication within 2 week dose Currently enrol another clinical study use investigational drug device within 30 day 5 halflives , whichever longer , precede informed consent Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week dose Engagement strenuous exercise within 2 week checkin ( eg , marathon runner , weight lifter )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>E2730</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>